VA Adds a Nondrug Wearable Option for Essential Tremor
Veterans living with essential tremor now have another treatment path inside the U.S. Department of Veterans Affairs. Encora Therapeutics says its FDA-cleared wrist device, Encora X1, is available to order through VA facilities, giving clinicians a nondrug option for patients whose tremor remains functionally limiting despite medication or for those who cannot use standard therapies.
The device arrives in a population where the burden is not small. More than 30,000 veterans receiving VA care had a recorded essential tremor diagnosis in a single year in a peer-reviewed national analysis of VA health records, and essential tremor affects an estimated 7.6 million people in the United States overall. In practice, that translates into a large pool of patients for whom shaking is not a cosmetic nuisance but a daily obstacle to eating, writing, drinking, or even using a phone with confidence.
One sentence captures the clinical appeal: this is tremor treatment without a pill or a procedure.
Mechanical Neurostimulation at the Wrist
Encora X1 is a wrist-worn device, roughly the size of a smartwatch, that delivers mechanical neurostimulation at the wrist. The therapy targets the median, radial, and ulnar peripheral nerve distributions, and the company says the device can be used either alongside medication or on its own. It is designed for on-demand use throughout the day, so patients can activate it when they need help with specific tasks rather than relying on continuous systemic therapy.
That design matters because essential tremor is often most disruptive in moments that are easy for others to overlook. A cup in one hand, a spoon at a meal, a signature on a form, a key pressed on a phone screen—each can become a test of coordination. A wearable intervention that can be turned on for the activity at hand fits the way many patients actually experience the disorder.
The company also describes a practical advantage for patients with implanted electrical devices, including pacemakers. Because Encora X1 uses mechanical rather than electrical stimulation, it carries no electrical contraindications, opening a path for patients who might otherwise be screened out of neuromodulation options. In a VA population with older age and multiple comorbidities, that kind of device compatibility can decide whether a therapy is even considered.
Functional Disability, Not Just Tremor Amplitude
Clinical attention in essential tremor often centers on the movement itself, but the meaningful endpoint is disability. A device can reduce visible shaking and still fail if it does not help a person complete a specific task with less frustration or less dependence on another person.
Encora’s clinical studies focused on that lived outcome. Effects were observed within about 15 minutes of use, and in a randomized, double-blind, sham-controlled study, 70% to 75% of participants achieved a one-point improvement in tremor-related disability during everyday tasks after 30 minutes of stimulation, compared with 48% of participants in the sham group. The company also said 96% of participants rated the therapy as comfortable all of the time.
Those numbers point to two features that matter in movement-disorder care: speed and tolerability. A therapy that works quickly can be matched to the exact moment a patient needs steadier hands, while a comfortable device is more likely to be worn often enough to matter in real life. If a patient cannot tolerate the intervention, the rest is academic.
Why This Fits the Treatment Gap
Treatment for essential tremor has long followed a familiar sequence: medications first, then procedural or surgical options for patients with refractory symptoms. Many patients sit in the middle. Their tremor is severe enough to interfere with routine life, but they may not be ready for invasive treatment, and they may not get enough relief from medication alone. Side effects can also limit the use of standard drugs, especially in older adults already managing several chronic conditions.
That middle group is where nondrug wearable therapy can have the most practical value. It does not replace established pharmacologic or procedural care, but it can broaden the menu for patients who want something less invasive than surgery and less systemically burdensome than another medication. For some veterans, especially those who are older, medically complex, or cautious about adding to an already long medication list, that difference is not theoretical; it determines whether treatment feels usable at all.
The VA channel may also speed adoption in a system where access pathways matter as much as device design. Once a therapy is available through federal procurement, clinicians have a clearer route to prescribing it, and that can shorten the gap between regulatory clearance and bedside use.
Practical Questions for Primary Care and Neurology
Primary care physicians often see essential tremor before a neurology referral ever happens. In those visits, the central question is not simply whether the tremor is present, but whether it is changing daily function, confidence, independence, or safety. The arrival of a wearable nondrug therapy gives clinicians another option to discuss when a patient says medication is inadequate, poorly tolerated, or simply not aligned with their preferences.
The device may also sharpen the conversation around treatment goals. A patient who wants steadier handwriting may value a different intervention than one whose main problem is spilling liquids or needing help at the dinner table. Because Encora X1 is designed for use during chosen activities, it lends itself to that sort of individualized planning.
Still, availability through the VA does not eliminate the need for careful selection. Prescription-only access means the care team must decide whether the device fits the patient’s tremor pattern, daily routine, and device compatibility profile. Veterans can ask their VA team whether it is appropriate for them, but the final decision will depend on the clinical context, not the diagnosis alone.
A New Option, with Familiar Constraints
Encora X1 expands the treatment conversation for a condition that can erode independence in small, relentless ways. A wearable that can be activated when a patient needs help with a task offers a different kind of control than medication taken on a fixed schedule.
The remaining questions are the ones clinicians will want answered in everyday use: how durable the benefit is across repeated wear, which patients derive the most functional improvement, and how well the device performs when the tremor is layered on top of the comorbidities common in veterans. The study data show rapid effect and good tolerability, but real-world practice will determine how often that translates into sustained functional gains for the people who need them most.